UPDATE 1-Lundbeck Q1 tops consensus, repeats outlook

* Q1 EBIT 1.25 bln DKK vs forecast 920 mln

* Blockbuster Cipralex sales +5 pct vs forecast +3 pct

* Repeats sees 2010 EBIT 3.0-3.4 bln DKK, up from 2.86 bln

* Says key products continued to gain market share in Q1

(Writes through, adds detail)

COPENHAGEN, May 6 (BestGrowthStock) – Danish drugmaker Lundbeck
(LUN.CO: ) posted an unexpected rise in first-quarter operating
profit, helped by stronger than expected sales of best seller
escitalopram, and repeated its full-year outlook.

Operating profit rose to 1.25 billion Danish crowns ($218
million) from 947 million a year earlier, the company said on
Thursday, against a mean forecast of 920 million in a Reuters
poll of analysts. [ID:nLDE6421E9]

Sales of antidepressant escitalopram rose 9 percent in the
United States, where it is marketed by Forest Laboratories
(FRX.N: ) under the name of Lexapro, to 727 million crowns, versus
an expected 1 percent drop.

Sales of Cipralex, under which name it is marketed
elsewhere, rose 5 percent to 1.45 billion crowns versus a
forecast 3 percent rise.

“The growth we have seen throughout the past year has
continued thanks to our main products, Cipralex, Ebixa and
Azilect, which are winning market share all over the world,”
Chief Financial Officer Anders Gotzsche said in an e-mailed
statement.

Lundbeck stood by guidance given in March for a 2010
operating profit of 3.0 to 3.4 billion crowns, up from 2.86
billion in 2009, and sales of 14.3 to 14.8 billion, up from 13.7
billion.

Stock Market Research Tools

(Reporting by Anna Ringstrom; Editing by David Holmes)
($1=5.736 Danish Crown)

UPDATE 1-Lundbeck Q1 tops consensus, repeats outlook